173 related articles for article (PubMed ID: 11388646)
61. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
62. Blockade of the renin-angiotensin system improves cerebral microcirculatory perfusion in diabetic hypertensive rats.
Estato V; Obadia N; Carvalho-Tavares J; Freitas FS; Reis P; Castro-Faria Neto H; Lessa MA; Tibiriçá E
Microvasc Res; 2013 May; 87():41-9. PubMed ID: 23466285
[TBL] [Abstract][Full Text] [Related]
63. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats.
Obata J; Nakamura T; Kuroyanagi R; Yoshida Y; Guo DF; Inagami T
Kidney Int Suppl; 1997 Dec; 63():S229-31. PubMed ID: 9407467
[TBL] [Abstract][Full Text] [Related]
64. Antiproteinuric effect of candesartan cilexetil in Japanese subjects with type 2 diabetes and nephropathy.
Haneda M; Kikkawa R; Sakai H; Kawamori R;
Diabetes Res Clin Pract; 2004 Oct; 66(1):87-95. PubMed ID: 15364166
[TBL] [Abstract][Full Text] [Related]
65. Temporary treatment of prepubescent rats with angiotensin inhibitors suppresses the development of hypertensive nephrosclerosis.
Nakaya H; Sasamura H; Hayashi M; Saruta T
J Am Soc Nephrol; 2001 Apr; 12(4):659-666. PubMed ID: 11274226
[TBL] [Abstract][Full Text] [Related]
66. Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition.
Oikawa T; Freeman M; Lo W; Vaughan DE; Fogo A
Kidney Int; 1997 Jan; 51(1):164-72. PubMed ID: 8995730
[TBL] [Abstract][Full Text] [Related]
67. A nonpeptide, piperidine renin inhibitor provides renal and cardiac protection in double-transgenic mice expressing human renin and angiotensinogen genes.
Major TC; Olszewski B; Rosebury W; Okerberg C; Carlson T; Ostroski R; Schroeder R; Kowala MC; Leadley R
Cardiovasc Drugs Ther; 2008 Dec; 22(6):469-78. PubMed ID: 18679781
[TBL] [Abstract][Full Text] [Related]
68. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.
Rodby RA; Rohde RD; Clarke WR; Hunsicker LG; Anzalone DA; Atkins RC; Ritz E; Lewis EJ
Nephrol Dial Transplant; 2000 Apr; 15(4):487-97. PubMed ID: 10727543
[TBL] [Abstract][Full Text] [Related]
69. Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype.
Kim S; Iwao H
J Hypertens Suppl; 1997 Dec; 15(6):S3-7. PubMed ID: 9493120
[TBL] [Abstract][Full Text] [Related]
70. Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus.
O'Donnell MP; Crary GS; Oda H; Kasiske BL; Powell JR; Keane WF
Kidney Int Suppl; 1997 Dec; 63():S218-20. PubMed ID: 9407464
[TBL] [Abstract][Full Text] [Related]
71. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy.
Matos JP; de Lourdes Rodrigues M; Ismerim VL; Boasquevisque EM; Genelhu V; Francischetti EA
Clin Nephrol; 2005 Sep; 64(3):180-9. PubMed ID: 16175942
[TBL] [Abstract][Full Text] [Related]
72. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
[TBL] [Abstract][Full Text] [Related]
73. High Fructose-Induced Hypertension and Renal Damage Are Exaggerated in Dahl Salt-Sensitive Rats via Renal Renin-Angiotensin System Activation.
Xu L; Hu G; Qiu J; Fan Y; Ma Y; Miura T; Kohzuki M; Ito O
J Am Heart Assoc; 2021 Jul; 10(14):e016543. PubMed ID: 34259014
[TBL] [Abstract][Full Text] [Related]
74. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
Mori-Takeyama U; Minatoguchi S; Murata I; Fujiwara H; Ozaki Y; Ohno M; Oda H; Ohashi H
Clin Exp Nephrol; 2008 Feb; 12(1):33-40. PubMed ID: 18175062
[TBL] [Abstract][Full Text] [Related]
75. Effects of candesartan on the renin system in conscious rats.
Wagner C; Kurtz A
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S169-71. PubMed ID: 9892158
[TBL] [Abstract][Full Text] [Related]
76. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.
Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE
Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273
[TBL] [Abstract][Full Text] [Related]
77. High-dose, not low-dose insulin increases the vasoconstrictor effect of norepinephrine in spontaneously hypertensive rats: effects of antihypertensive treatment.
Rizzoni D; Porteri E; Piccoli A; Castellano M; Pasini G; Guelfi D; Muiesan ML; Rosei EA
J Vasc Res; 1999; 36(5):393-403. PubMed ID: 10559680
[TBL] [Abstract][Full Text] [Related]
78. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
Lafayette RA; Mayer G; Park SK; Meyer TW
J Clin Invest; 1992 Sep; 90(3):766-71. PubMed ID: 1522231
[TBL] [Abstract][Full Text] [Related]
79. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.
Andersen S; Tarnow L; Rossing P; Hansen BV; Parving HH
Kidney Int; 2000 Feb; 57(2):601-6. PubMed ID: 10652037
[TBL] [Abstract][Full Text] [Related]
80. Effects of antihypertensive drugs in experimental type 2 diabetes-related nephropathy.
Blanco S; Penin R; Casas I; López D; Romero R
Kidney Int Suppl; 2002 Dec; (82):S27-31. PubMed ID: 12410851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
